Your browser doesn't support javascript.
loading
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
Yang, James C; Haworth, Leah; Sherry, Richard M; Hwu, Patrick; Schwartzentruber, Douglas J; Topalian, Suzanne L; Steinberg, Seth M; Chen, Helen X; Rosenberg, Steven A.
Affiliation
  • Yang JC; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md 20892, USA. james_yang@nih.gov
N Engl J Med ; 349(5): 427-34, 2003 Jul 31.
Article in En | MEDLINE | ID: mdl-12890841
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Endothelial Growth Factors / Lymphokines / Tumor Suppressor Proteins / Ubiquitin-Protein Ligases / Kidney Neoplasms / Antibodies, Monoclonal Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: N Engl J Med Year: 2003 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Endothelial Growth Factors / Lymphokines / Tumor Suppressor Proteins / Ubiquitin-Protein Ligases / Kidney Neoplasms / Antibodies, Monoclonal Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: N Engl J Med Year: 2003 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos